Navigating The Evolving Landscape of Adalimumab Biosimilars for Inflammatory Disease - Episode 8

Selecting Between Adalimumab Biosimilars for Your Patients

Published on: 
, , , ,

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The discussion revolves around how to choose the appropriate biosimilar for patients. In dermatology, options are limited, especially for conditions like psoriasis where newer treatments may outperform existing biosimilars. However, for conditions like hidradenitis, where choices are scarce, biosimilars offer a straightforward solution. The growth of biosimilars is anticipated to provide more options for clinicians, allowing them to select treatments based on efficacy and patient insurance coverage.

Clinicians often consider insurance formularies to anticipate the most easily approved biosimilar for each patient. In conditions like inflammatory bowel disease (IBD), certain biologics like Adalimumab play a significant role in treatment, leading to the proliferation of biosimilars. While payer preferences often influence prescribing decisions, clinicians prioritize factors like citrate-free formulations, small volume, high concentration, and robust patient support programs when choosing biosimilars, aiming for broader uptake and patient adherence.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.